Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 8/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | GUSB | P08236 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127509 | 0.93 | TRPV4 (0.41) | TP53ALDH1A1ALOX15TSHRMAPK1 | |
| SCHEMBL4142748 | 0.91 | TRPV4 (0.49) | ALDH1A1TSHRMAPK1TRPV4L3MBTL1 | |
| SCHEMBL4139656 | 0.81 | TRPV4 (0.40) | TRPV4GAA | |
| SCHEMBL4152821 | 0.79 | TRPV4 (0.45) | TRPV4L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL4133461 | 0.78 | TRPV4 (0.47) | ALDH1A1TRPV4L3MBTL1GAAMAPT | |
| SCHEMBL4140703 | 0.78 | TRPV4 (0.37) | ALDH1A1TRPV4GAA | |
| SCHEMBL4141257 | 0.77 | CCR1 (0.41) | TP53ALDH1A1TRPV4GAAMAPT | |
| SCHEMBL4141037 | 0.77 | BMP1 (0.37) | TRPV4MAPTFABP4SMN1; SMN2 | |
| SCHEMBL4135938 | 0.75 | BMP1 (0.36) | TRPV4FABP4 | |
| SCHEMBL5435367 | 0.75 | BMP1 (0.40) | ALDH1A1MAPK1TRPV4FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | TP53 4387/4885ALDH1A1 1565/4885ALOX15 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.